Proteomics analysis of potential serum biomarkers for insulin resistance in patients with polycystic ovary syndrome

Li,Li; Zhang,Jing; Zeng,Jing; Liao,Biling; Peng,Xiuhong; Li,Tiantian; Li,Jieming; Tan,Qiuxiao; Li,Xiaofang; Yang,Ying; Chen,Zhijing; Liang,Zhijiang

doi:10.3892/ijmm.2020.4522

Proteomics analysis of potential serum biomarkers for insulin resistance in patients with polycystic ovary syndrome

Authors:
- Li Li
- Jing Zhang
- Jing Zeng
- Biling Liao
- Xiuhong Peng
- Tiantian Li
- Jieming Li
- Qiuxiao Tan
- Xiaofang Li
- Ying Yang
- Zhijing Chen
- Zhijiang Liang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Guangdong Women and Children Hospital, Guangzhou, Guangdong 510010, P.R. China, Department of Gynecology, Family Planning Research Institute of Guangdong Province, Guangzhou, Guangdong 510600, P.R. China, Department of Public Health, Guangdong Women and Children Hospital, Guangzhou, Guangdong 510010, P.R. China
Published online on: March 3, 2020 https://doi.org/10.3892/ijmm.2020.4522
Pages: 1409-1416
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to identify potential serum biomarkers for insulin resistance (IR) in patients with polycystic ovary syndrome (PCOS) by comparing the differences in serum protein expression levels between PCOS patients with and without IR. PCOS patients aged from 18 to 35 years were recruited at Guangdong Women and Children's Hospital from January, 2013 to February, 2014. A total of 218 PCOS patients were enrolled and divided into the insulin resistance (PCOS‑IR) and non‑insulin resistance (PCOS‑NIR) groups according to their homeostasis model assessment of insulin resistance. Two‑dimensional difference gel electrophoresis (2D‑DIGE) and matrix‑assisted laser desorption/ionization time‑of‑flight mass spectrometry (MALDI‑TOF‑MS/MS) techniques were used to identify differences in protein expression levels between the PCOS‑IR and PCOS‑NIR groups. The present study demonstrated that the total cholesterol (TCH), triglycerides (TG), low‑density lipoprotein (LDL), fasting plasma glucose (FPG), 3‑h blood glucose (3hBG) and uric acid (UA) levels in the PCOS‑IR group were higher than those in the PCOS‑NIR group (P<0.05). Between the PCOS‑IR and PCOS‑NIR groups, a total of 20 differentially expressed protein spots were detected by 2D‑DIGE. Among these, 4 proteins, namely afamin, serotransferrin, complement C3 and apolipoprotein C3 (APOC3), were also identified by MALDI‑TOF‑MS/MS. The alteration of APOC3 was further confirmed by western blot analysis and enzyme‑linked immunosorbent assay (ELISA). The present study also confirmed that the expression level of APOC3 was positively associated with the homeostasis model assessment of insulin resistance (HOMA‑IR). On the whole, the data indicate that APOC3 may be a potential diagnostic marker for PCOS‑IR patients.

View Figures

View References

1	Escobar-Morreale HF: Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 14:270–284. 2018. View Article : Google Scholar : PubMed/NCBI
2	Wolf WM, Wattick RA, Kinkade ON and Olfert MD: Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Env Res Pub He. 15:E25892018. View Article : Google Scholar
3	Sirmans SM and Pate KA: Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 6:1–13. 2013. View Article : Google Scholar :
4	Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R and Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 98:4565–4592. 2013. View Article : Google Scholar : PubMed/NCBI
5	Azziz R, Marin C, Hoq L, Badamgarav E and Song P: Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 90:4650–4658. 2005. View Article : Google Scholar : PubMed/NCBI
6	Burghen GA, Givens JR and Kitabchi AE: Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 50:113–116. 1980. View Article : Google Scholar : PubMed/NCBI
7	Dunaif A, Segal KR, Futterweit W and Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38:1165–1174. 1989. View Article : Google Scholar : PubMed/NCBI
8	Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G and Yen SS: Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: Common and distinct features. J Clin Endocrinol Metab. 81:2854–2864. 1996.PubMed/NCBI
9	Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ and Stepto NK: Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 31:2619–2631. 2016. View Article : Google Scholar : PubMed/NCBI
10	Palomba S, Falbo A, Russo T, Rivoli L, Orio M, Cosco AG, Vero R, Capula C, Tolino A, Zullo F, et al: The risk of a persistent glucose metabolism impairment after gestational diabetes mellitus is increased in patients with polycystic ovary syndrome. Diabetes care. 35:861–867. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhang J, Li JM, Deng QS, Chen WF, Peng XH and Li L: Analysis of the metabolic characteristics of polycystic ovary syndrome under different states. Chin J Pract Gynecol Obstet. 32:446–449. 2016.
12	Rizzo M, Tyndall EK, Frontoni S, Jacoangeli F, Sarlo F, Panebianco F, Mistorni A, Di Renzo L, Calafiore R, Luca G and De Lorenzo A: Rapid and easy assessment of insulin resistance contributes to early detection of polycystic ovary syndrome. J Endocrinol Invest. 36:527–530. 2013.PubMed/NCBI
13	Okamura Y, Saito F, Takaishi K, Motohara T, Honda R, Ohba T and Katabuchi H: Polycystic ovary syndrome: Early diagnosis and intervention are necessary for fertility preservation in young women with endometrial cancer under 35 years of age. Reprod Med Biol. 16:67–71. 2017. View Article : Google Scholar : PubMed/NCBI
14	Li X, Guo YR, Lin JF, Feng Y, Billig H and Shao R: Combination of Diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance. J Cancer. 5:173–181. 2014. View Article : Google Scholar : PubMed/NCBI
15	Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM and Ravussin E: Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care. 35:1605–1610. 2012. View Article : Google Scholar : PubMed/NCBI
16	De Souza AL, Batista GA and Alegre SM: Assessment of insulin sensitivity by the hyperinsulinemic euglycemic clamp: Comparison with the spectral analysis of photoplethysmography. J Diabetes Complications. 31:128–133. 2017. View Article : Google Scholar
17	Kurl S, Zaccardi F, Onaemo VN, Jae SY, Kauhanen J, Ronkainen K and Laukkanen JA: Association between HOMA-IR, fasting insulin and fasting glucose with coronary heart disease mortality in nondiabetic men: A 20-year observational study. Acta Diabetol. 52:183–186. 2015. View Article : Google Scholar
18	Peplies J, Jiménez-Pavón D, Savva SC, Buck C, Günther K, Fraterman A, Russo P, Iacoviello L, Veidebaum T, Tornaritis M, et al: Percentiles of fasting serum insulin, glucose, HbA1c and HOMA-IR in pre-pubertal normal weight European children from the IDEFICS cohort. Int J Obesity (Lond). 38(Suppl 2): S39–S47. 2014. View Article : Google Scholar
19	Mossmann M, Wainstein MV, Gonçalves SC, Wainstein RV, Gravina GL, Sangalli M, Veadrigo F, Matte R, Reich R, Costa FG and Bertoluci MC: HOMA-IR is associated with significant angiographic coronary artery disease in non-diabetic, non-obese individuals: A cross-sectional study. Diabetol Metab Syndr. 7:1002015. View Article : Google Scholar
20	Viswanathan S, Unlu M and Minden JS: Two-dimensional difference gel electrophoresis. Nat Protoc. 1:1351–1358. 2006. View Article : Google Scholar
21	McNamara LE, Dalby MJ, Riehle MO and Burchmore R: Fluorescence two-dimensional difference gel electrophoresis for biomaterial applications. J R Soc Interface. 7(Suppl 1): S107–S118. 2010. View Article : Google Scholar :
22	Yin JH, Li M, Xu L, Wang Y, Cheng H, Zhao XY and Mi J: Insulin resistance determined by Homeostasis Model Assessment (HOMA) and associations with metabolic syndrome among Chinese children and teenagers. Diabetol Metab Syndr. 5:712013. View Article : Google Scholar : PubMed/NCBI
23	Li R, Yu G, Yang D, Li S, Lu S, Wu X, Wei Z, Song X, Wang X, Fu S and Qiao J: Prevalence and predictors of metabolic abnormalities in Chinese women with PCOS: A cross-sectional study. BMC Endocr Disord. 14:762014. View Article : Google Scholar
24	Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM and Voshol PJ: Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes. 54:664–671. 2005. View Article : Google Scholar : PubMed/NCBI
25	Lee HY, Birkenfeld AL, Jornayvaz FR, Jurczak MJ, Kanda S, Popov V, Frederick DW, Zhang D, Guigni B, Bharadwaj KG, et al: Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology. 54:1650–1660. 2011. View Article : Google Scholar : PubMed/NCBI
26	Avall K, Ali Y, Leibiger IB, Leibiger B, Moede T, Paschen M, Dicker A, Daré E, Köhler M, Ilegems E, et al: Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes. Proc Natl Acad Sci USA. 112:E2611–E2619. 2015. View Article : Google Scholar
27	Ruiz-Narváez EA, Yang Y, Nakanishi Y, Kirchdorfer J and Campos H: APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J Lipid Res. 46:2605–2613. 2005. View Article : Google Scholar : PubMed/NCBI
28	Kavo AE, Rallidis LS, Sakellaropoulos GC, Lehr S, Hartwig S, Eckel J, Bozatzi PI, Anastasiou-Nana M, Tsikrika P and Kypreos KE: Qualitative characteristics of HDL in young patients of an acute myocardial infarction. Atherosclerosis. 220:257–264. 2012. View Article : Google Scholar
29	Blankenhorn DH, Alaupovic P, Wickham E, Chin HP and Azen SP: Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 81:470–476. 1990. View Article : Google Scholar : PubMed/NCBI
30	Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA and Braunwald E: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 102:1886–1892. 2000. View Article : Google Scholar : PubMed/NCBI
31	Larsson M, Vorrsjö E, Talmud P, Lookene A and Olivecrona G: Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem. 288:33997–34008. 2013. View Article : Google Scholar : PubMed/NCBI
32	Maeda N, Li H, Lee D, Oliver P, Quarfordt SH and Osada J: Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem. 269:23610–23616. 1994.PubMed/NCBI